loading page

Neonatal outcomes after neuraminidase inhibitor use during pregnancy: a meta-analysis of cohort studies
  • +2
  • Jiangshan Lian,
  • Munire Adilijiang,
  • Caihua Chang,
  • Hai-yin Jiang,
  • Yongping Zhang
Jiangshan Lian
Author Profile
Munire Adilijiang
Author Profile
Caihua Chang
Author Profile
Hai-yin Jiang
Author Profile
Yongping Zhang
Author Profile


AIM: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase-inhibitor antiviral medications during pregnancy has not been well described. METHODS: A systematic review and meta-analysis were performed to evaluate the adverse neonatal outcomes associated with exposure to neuraminidase inhibitors during pregnancy. The PubMed, Embase, and Cochrane Library databases were searched to identify potential studies for inclusion. RESULTS: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase-inhibitor medication during pregnancy were included. Exposure to a neuraminidase inhibitor during pregnancy was not associated with an increased risk of congenital malformation (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.72–1.12, P = 0.341), low Apgar score (OR 0.96, 95% CI 0.77–1.2, P = 0.733), or preterm birth (OR 0.99, 95% CI 0.89–1.09, P = 0.771) compared with no exposure. However, exposure to a neuraminidase inhibitor was associated with a reduced risk of low birth weight (OR 0.79, 95% CI 0.68–0.92, P = 0.002) and giving birth to a small-for-gestational-age infant (OR 0.78, 95% CI 0.69–0.88, P < 0.001). Further analyses limited to oseltamivir exposure were consistent with the overall results. CONCLUSION: Exposure to neuraminidase-inhibitor medication during pregnancy does not appear to be associated with adverse neonatal outcomes. We recommend further studies to investigate this association, which will help clinicians determine whether to prescribe a neuraminidase inhibitor during pregnancy.

Peer review status:ACCEPTED

13 May 2021Submitted to British Journal of Clinical Pharmacology
17 May 2021Submission Checks Completed
17 May 2021Assigned to Editor
23 May 2021Reviewer(s) Assigned
11 Jun 2021Review(s) Completed, Editorial Evaluation Pending
21 Jun 2021Editorial Decision: Revise Major
28 Jun 20211st Revision Received
29 Jun 2021Submission Checks Completed
29 Jun 2021Assigned to Editor
29 Jun 2021Review(s) Completed, Editorial Evaluation Pending
03 Jul 2021Reviewer(s) Assigned
31 Jul 2021Editorial Decision: Accept